Prednisolone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Prednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Prednisolone is a synthetic glucocorticoid widely used to treat inflammatory, allergic, and autoimmune conditions through its anti-inflammatory and immunosuppressive actions. The TxGNN model predicts it may be effective for Alopecia Areata, with 1 highly relevant completed Phase 4 RCT, 2 additional supporting clinical trials, and 20 publications (including 1 placebo-controlled RCT and multiple systematic reviews) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no Taiwan license records); prednisolone is a systemic corticosteroid broadly indicated for inflammatory, allergic, and autoimmune conditions |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, prednisolone is a synthetic glucocorticoid; its anti-inflammatory and immunosuppressive efficacy in classic corticosteroid indications (autoimmune, allergic, and inflammatory conditions) is well established, and mechanistically this immune-modulating action may be applicable to alopecia areata (AA).
AA is a T-cell–mediated autoimmune disease in which collapse of the hair follicle’s immune privilege drives an inflammatory attack on the follicle. Prednisolone suppresses peri-follicular T-cell infiltration and the associated cytokine cascade, directly addressing this pathophysiology. Notably, systemic pulse-dose corticosteroid therapy is already a recognized (though largely off-label) treatment approach in dermatology for severe, treatment-resistant AA — this is not a purely theoretical extrapolation but an extension of existing clinical practice.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Evaluated oral mega-pulse methylprednisolone (same glucocorticoid class as prednisolone) in patients with severe, treatment-resistant alopecia areata; systemic pulse glucocorticoids showed efficacy in widespread AA |
| NCT07101471 | N/A (Observational) | Completed | 296 | Real-world safety/effectiveness study of tofacitinib in alopecia; participants received tofacitinib with or without adjuvant prednisolone |
| NCT01017510 | N/A | Unknown | 20 | Compared needle-free (DERMOJET) vs conventional syringe delivery of intralesional corticosteroid for alopecia areata |
Note: Several additional trials in the underlying evidence pack (e.g., systemic lupus erythematosus studies) were excluded from this table as they do not directly involve alopecia areata or prednisolone.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15692475 | 2005 | RCT | J Am Acad Dermatol | First randomized, placebo-controlled trial of oral pulse prednisolone therapy in alopecia areata |
| 37870096 | 2023 | Review (Network Meta-analysis) | Cochrane Database Syst Rev | Network meta-analysis comparing immunosuppressants, hair growth stimulants, and immunotherapy for AA |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Reviews efficacy, relapse rates, adverse effects, and prognostic factors of corticosteroid pulse therapy in AA |
| 30191561 | 2019 | Systematic Review | Australas J Dermatol | Systematic review of systemic treatments for AA, alopecia totalis, and universalis (1946–2018) |
| 35986630 | 2022 | Retrospective Cohort | Dermatol Ther | Methylprednisolone alone vs combined with methotrexate in extensive AA |
| 36461625 | 2023 | Review | Pediatr Dermatol | Review of pulse-dose corticosteroid dosing/administration regimens for pediatric AA |
| 28140540 | 2017 | Cohort | J Dtsch Dermatol Ges | Sequential high- then low-dose systemic corticosteroid therapy in severe childhood AA |
| 21572877 | 2009 | Clinical Study | Dermatoendocrinology | Medium-dose prednisolone pulse therapy outcomes in AA |
| 30294905 | 2019 | Mechanistic Study | J Cosmet Dermatol | Serum/tissue TNF-α alterations proposed as a mechanism for oral pulse steroid effect in AA |
| 18608727 | 2008 | Cohort | J Dermatolog Treat | Combination therapy of cyclosporine and methylprednisolone in severe AA |
US Market Information
Prednisolone is currently not marketed under this evidence pack (0 licenses on record; market status: 未上市). No authorization/product records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed Phase 4 trial (NCT01167946) directly evaluates pulse-dose glucocorticoid therapy in severe treatment-resistant AA, supported by a placebo-controlled RCT (PMID 15692475) and multiple systematic reviews/Cochrane analyses confirming corticosteroid pulse therapy as an established, mechanistically-grounded (though largely off-label) dermatology practice. However, no Taiwan-specific regulatory, labeling, or safety data exist for this evidence pack, so guardrails are required before any clinical or commercial pathway is pursued.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (blocking data gap, DG001)
- Detailed mechanism of action (MOA) data from DrugBank (DG002)
- Confirmation of dosing regimen and route compatibility for pulse corticosteroid therapy specific to AA
- Local market/licensing assessment for prednisolone products relevant to this potential indication expansion
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.